Abstract
PURPOSE: Cryoprecipitate has been covered by Japanese national health insurance since 2020 for cardiopulmonary bypass (CPB)-induced hypofibrinogenemia. This study evaluated the clinical efficacy of in-house cryoprecipitate use in patients undergoing CPB. METHODS: A total of 1357 patients were divided into 2 groups before and after cryoprecipitate introduction in February 2020 (Group A, n = 685; Group B, n = 672). Propensity score matching also compared 205 pairs between transfused patients in Group A (Group A', n = 597) and those receiving cryoprecipitate in Group B (Group B', n = 222). RESULTS: Cryoprecipitate was used in 222 patients (37%) in Group B. While overall transfusion rates did not differ significantly, postoperative red blood cell (20% vs 13%, p <0.01) and platelet concentrate (PC) (35% vs 12%, p <0.01) use were significantly lower in Group B. In the matched cohorts, including ~70% undergoing aortic surgery, postoperative PC use was significantly reduced in Group B' (26% vs 18%, p = 0.04). CONCLUSIONS: In-house cryoprecipitate use was associated with reduced postoperative PC transfusion, particularly in aortic surgery involving prolonged CPB and deep hypothermic circulatory arrest. A cryoprecipitate-centered hemostatic strategy, supplementing multiple coagulation factors beyond fibrinogen, may be effective in complex CPB procedures.